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Abstract
Purpose: To report the results of a patient’s tailored therapeutic approach using a second course of interventional 
radiotherapy (brachytherapy) in patients with locally recurrent uveal melanoma. 
Material and methods: Patients who had already undergone ocular brachytherapy treated at our IOC (Interven-
tional Oncology Center) were considered. Five patients who has received a second course of treatment with a plaque 
after local recurrences were included in our study. Re-irradiation was performed with Ruthenium-106 (prescribed dose 
to the apex 100 Gy) or with Iodine-125 plaques (prescribed dose to the apex 85 Gy). Moreover, a systematic literature 
search was conducted through three electronic databases, including Medline/PubMed, Scopus, and Embase.
Results: All patients were initially treated with Ruthenium-106 plaque; the re-irradiation was performed with 
Ruthenium-106 plaque in three cases and with Iodine in two cases. Mean time between the first and the second plaque 
was 56.8 months (range, 25-93 months). Local tumor control rate was 100%, no patient underwent secondary enucle-
ation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment. After 
a median follow-up of 44.2 months (range, 26-65 months) from re-treatment, all patients experienced worsening of the 
visual acuity (median visual acuity was 0.42 at time of recurrence and decline to 0.24 at the most recent follow-up); 
cataract occurred in two cases, no patient developed scleral necrosis. We considered 2 papers for a systematic review.
Conclusions: In selected cases, especially in presence of marginal local recurrence, a personalized re-treatment strat-
egy with a plaque may offer high probability of tumor control and organ preservation but worsening of visual acuity. 
J Contemp Brachytherapy 2019; 11, 1: 54–60 
DOI: https://doi.org/10.5114/jcb.2019.82888
Key words: uveal melanoma, brachytherapy, re-treatment, re-irradiation. 
Purpose 
Episcleral plaque radiotherapy is an effective method 
of controlling uveal melanoma locally as confirmed by 
long-term results [1]. Unfortunately, failure of the radio-
active plaque to control tumor growth is occasionally ob-
served [2]. Data published in a review by Chang presents 
local failure rates following various forms of conservative 
treatments for uveal melanoma [3]: among 49 identified 
studies, the local treatment failure rate ranged from 0% 
to 55.6%. The two most widely used forms of interven-
tional radiation therapy, Iodine-125 and Ruthenium-106 
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brachytherapy, were associated with a weighted aver-
age of local recurrence rate of 9.6%. Furthermore, proton 
beams resulted in 4.2%, while transpupillary thermother-
apy had the largest reported variation of local treatment 
failure from 0% to 55.6%, with a weighted average of 
20.8%. It is possible to observe different kinds of recur-
rences and a specific dependence from their growth pat-
terns; they may take the form of marginal, central, diffuse, 
distant, or extrascleral extensions. Marginal recurrences 
might be related to an insufficient radiation dose to the 
tumor border following an underdosage to the tumor’s 
edge mainly due to the microscopic disease spread or dis-
placement of the plaque. 
Distant recurrences are rare, and they might be 
caused by melanoma cell spreading throughout the an-
terior chamber or by the extension of the tumor along the 
ciliary body. As suggested by some authors, they may be 
present due to the migration of tumor cells into the exu-
dative retinal detachment [4]. The work of Caujolle et al. 
analyzed the prognosis of different types of uveal mel-
anoma recurrences and reported superior survival rate 
of marginal recurrence compared to other recurrences in 
patients treated with proton beams [5]. 
Usually, the treatment approach for a local recur-
rence is an enucleation, resulting in several side effects, 
including poor esthetic results and visual loss [6], which 
has been investigated and related to tumor localization 
and dose to the fovea [7]. The main aim of this work is 
to evaluate outcomes of recurrence re-treatment using 
eye plaque interventional radiotherapy by analyzing the 
institutional experience and performing a systematic re-
view of the literature. 
Material and methods 
The records of patients treated between December 
2006 and December 2014 at our institutional IOC [8] 
(Interventional Oncology Center) [9] for primary uveal 
melanoma were retrospectively reviewed [10]. All pa-
tients have been treated with Ruthenium-106 plaques or 
Iodine-125 seeds, and the tumor’s apex prescription dose 
was 100 Gy and 85 Gy, respectively. For the treatment, 
the adequate size and shape of the episcleral plaque has 
been selected to provide a 1 mm margin in all directions 
of the base of the tumor. The dose prescription and the 
CTV definition have been the same for the first course 
and for the re-treatment. After analyzing all recurrences, 
patients with marginal recurrences located at the equa-
tor, re-treated with the use of interventional radiotherapy 
were selected for the study. 
The exclusion criteria were posterior location of the 
recurrence and diffuse or global recurrence. 
A systematic literature search was conducted through 
three electronic databases from their inception until Feb-
ruary 2018, including Medline/Pubmed, Scopus, and 
Embase. The following medical subject heading (MeSH) 
terms were used: “uveal melanoma”, “recurrence”, 
“brachytherapy” (“uveal melanoma” [supplementary 
concept] or “uveal melanoma” [all fields], and (“recur-
rence” [MeSH terms] or “recurrence” [all fields]), and 
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fields]). Two independent authors (BF, MGS) screened 
citations at the title and abstract level to identify poten-
tially relevant studies without any duplication. Eligible 
citations were retrieved for full text review, and any un-
certainty was resolved by 2 other radiation oncologist 
experts from ocular interventional radiotherapy (LT, RA) 
and 2 ophthalmologist experts of the same field (MMP, 
AS) from the same institution. An independent review 
of the data was performed by 4 radiation oncologists 
(VL, GK, RM, SC) from 4 different radiotherapy centers 
(Perugia, Lubeck, Navarra, Bologna) and by a medical 
physicist (LA). The senior members of the Gemelli Ocular 
Melanoma team dedicated to clinical decision-making in 
ocular cancer, reviewed the paper and gave the final ap-
proval to the manuscript (MAG, VV, MAB). 
Results 
From our database [11], 23 patients affected by recur-
rence were considered in this analysis. Among these cas-
es of local recurrences, 14 were treated with enucleation, 
1 with trans scleral resection, 3 with proton beam, and 
5 were selected to undergo a second cycle of brachythera-
py. The characteristics of this radioactive plaque re-treat-
ed group of five patients with locally recurrent uveal mel-
anomas are reported in Table 1. The median apex height 
was 3.33 mm at the time of initial diagnosis and 3.01 at 
the time of recurrence. The mean time between the first 
and the second plaque was 56.8 months. All patients were 
initially treated with Ruthenium-106 plaque. The re-irra-
diation was performed with Ruthenium-106 plaque in 
three cases and with Iodine-125 seeds in two cases, and 
the mean dose delivered to the sclera was 340 Gy in the 
first treatment and 206 Gy in the second plaque. The 
choice of the kind of radionuclide was based on the final 
dose to the sclera. The mean total dose delivered to the 
sclera was 495 Gy. No patients developed scleral necrosis. 
After a mean follow-up of 44.2 months, the local tumor 
control rate was 100%, no patient underwent secondary 
enucleation owing to re-treatment failure. Distant metas-
tasis occurred in 1 patient after 6 months from re-treat-
ment (Table 2). 
All patients experienced worsening of the visual acu-
ity. The median visual acuity at time of local recurrence 
was 0.42, after a median follow-up of 44.2 months (range, 
26-65 months). From the time of re-treatment, all patients 
evolved, as expected, towards a worsening of the visual 
acuity, with a median decline to 0.24 at the most recent fol-
low-up. No patient developed scleral necrosis [12]. After 
the re-treatment, cataract occurred in two cases (Table 3). 
Figure 1 presents visible tumor’s regression after 
treatment of a patient included in the study. In Figure 2, 
the visual acuity before and after re-treatment at the last 
follow-up of all patients included in the study are pre-
sented. Regarding the systematic review, 103 papers 
were identified and carefully evaluated, out of which 
72 papers were excluded because BT re-irradiation was 
not the primary topic of the paper, 24 papers were exclud-
ed because BT was used as the first line treatment and not 
in the setting of a recurrence, 4 papers were excluded be-
cause authors reported a mixed cases of patients with re-
current disease treated using several modalities, includ-




Total dose to 
sclera (Gy) 
Scleral necrosis Enucleation Thickness  
reduction 
Metastasis 
1 65 421.5 0 0 54.9% M0 
2 38 790.6 0 0 11% M0 
3 50 309.1 0 0 53.7% M0 
4 42 471.7 0 0 37.10% M0 
5 26 483.1 0 0 22.84% M1 
Mean 44.2 495.20 0 0 35.9% 1/5 (20%) 
Table 3. Visual acuity troughout follow-up
Radionuclide Visual acuity  









1 Ru-106 20/20 65 Ru-106 20/40 1
2 Ru-106 20/400 38 I-125 Counting finger 0
3 Ru-106 20/40 50 I-125 20/80 0
4 Ru-106 20/80 42 Ru-106 20/160 1
5 Ru-106 20/32 26 Ru-106 20/40 0
Mean 20/50 44.2 20/80 
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Fig. 1. A, B) Choroidal melanoma before and after treatment, showing the appearance of an extensive scar area; C, D) Ultraso-





Fig. 2. Differences in visual acuity at the time of recurrence 
and after retreatment
 VA at time of recurrence 
















Fig. 3. Search results of literature
103 papers evaluated 
2 papers included
72 BT reirradiation not primary topic 
     24 not reirradiation 
        5 BT reirradiation with in a mixed case 
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ing BT with Ru-106, but with no chance to extrapolate the 
specific data. Eventually, only two papers dealing with 
the specific topic of our review were found (Figure 3). 
Discussion 
Local tumor control is a critical goal in patients’ man-
agement of the entire head and neck region [13], espe-
cially in case of choroidal melanoma, since patients with 
local treatment failure are prone to an increased risk of 
metastasis and an increased morbidity of an eye and vi-
sion [14]. 
As there is no established management for cases of 
local treatment failure, the therapeutic approach depends 
on the extent and the location of the recurrence and re-
mains a case-by-case decision; even though enucleation is 
still the most used procedure for recurrent melanoma [15]. 
Important tumor and treatment features [16,17] as 
well as the total dose of treatment may influence the out-
comes (as reported in literature) of both Iodine-125 [18] 
and Ruthenium-106 [19,20]. That is why there is an in-
creasing evidence in literature towards supporting a per-
sonalized approach for shaping target-specific dose dis-
tributions [21]. 
In this study, we report our single institution experi-
ence about the use of a second course of brachytherapy 
for the re-treatment of patients with choroidal melanoma 
recurrences. The enrolled patients were selected accord-
ing the following criteria: the presence of a marginal re-
currence and a non-posterior localization of the tumor. 
Patients with a diffuse or global recurrence were not 
considered eligible for re-treatment with plaque, since 
these types of recurrences are not easily covered by 
a plaque and might cause tumor re-growth. 
Patients with posterior tumor recurrence can be elect-
ed for proton beam re-treatment or enucleation, since 
more posterior or close to the optic disc tumor locations 
are more challenging; plaques cannot be placed accurately 
to cover the tumors [22]. Moreover, during brachytherapy 
treatment for posterior uveal melanomas, Almony et al. 
[23] reported that posterior tilting of a plaque is an im-
portant factor contributing to local failure. The tilting and 
the consequent higher failure rate for posterior tumors 
could be explained by the difficult surgical access and vi-
sualization caused by the orbital anatomy. Furthermore, 
the optic nerve sheath caused by the obstruction as well 
the compression of the inferior oblique muscle, the pos-
terior ciliary vessels, and nerves can impede to achieve 
a close plaque placement to the sclera [24]. 
In our opinion, in the cases of a re-treatment with 
plaques, there is an increased risk of posterior tumors 
tilting, although, in our practice, we use intraoperative 
ultrasonography for optimal plaque placement [25]. 
Additionally, epibulbar tissue and inferior oblique 
muscle fibrosis caused by the first irradiation may create 
problems to achieve a close apposition of the plaque to 
the sclera during a second treatment procedure. For these 
reasons, we excluded the posterior uveal melanoma re-
currence from the second course of brachytherapy treat-
ment. In patients with marginal recurrences, the failure 
of the first brachytherapy might be due to an insufficient 
radiation dose to the tumor border following errors in 
treatment planning or in the irradiation delivery, as men-
tioned by Desjardins et al. [26]. Moreover, as suggested by 
Caujolle et al. [5], very large or thin melanomas are more 
likely to reappear, because of the difficulty to properly 
definie the lateral tumor limits by an ultrasound. In an 
analysis of prognosis of different types of uveal melano-
ma recurrences, the same authors reported superior sur-
vival rate of marginal recurrences compared to that of the 
other recurrences in patients treated with proton beams. 
Marucci et al. [27] supposed that the marginal recurrences 
represent a less aggressive subtype or phenotype than the 
other recurrences, as they found lower mortality rate in 
patients with marginal recurrences treated with a second 
course of proton beam than in recurrences treated with 
enucleation. We found only two papers dealing with the 
specific topic of our review (Figure 2). Gaspar de Souza 
Neves et al. [28] report seven patients who underwent 
re-irradiation with Ru-106 plaque for uveal melanoma 
recurrences. The median time between the first treatment 
and re-irradiation was 24 months and after a median fol-
low-up of 30 months, they found 87.5% of 2-year local 
control and 60% of progression-free survival. In terms of 
side effects, the authors specified that all patients evolved 
with worsening of the visual acuity and cataract; other ob-
served complications were maculopathy and glaucoma. 
In another study by King et al. [29] included twenty-seven 
patients who were re-irradiated with I-125, the median 
follow-up from initial treatment was 100 months, with 
a median time to local recurrence of 43 months. The me-
dian follow-up after re-treatment was 47 months and the 
reported 5-year local control was 77.2%. Furthermore, the 
authors reported that the visual acuity was 20/70 (20/20 
to counting fingers at 1 foot) at the time of recurrence and 
declined to count fingers (20/25 to hand motion) at their 
most recent follow-up examination. A comprehensive 
view of these data is shown in Table 4. In his study, Gas-
par de Souza Neves et al. [28] did not specify the kind of 
recurrence, while 44.4% of patients re-treated with plaque 
studied by King et al. [29] were diagnosed with marginal 
recurrences and 55% by diffuse recurrence. No differenc-
Table 4. Studies available in literature about uveal melanoma retreated with brachytherapy
Author Year No. of patients Radionuclide used  
for re-irradiation
FU Local control
Tagliaferri et al. 2019 5 Ru-106 or I-125 44.2 months 100% at 3 years 
King et al. [29] 2017 27 I-125 47 months 87.5% at 2 years 
Gaspar de Souza 
Neves et al. [28] 
2014 7 Ru-106 or I-125 30 months 77.2% at 5 years 
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es were reported from the latter author among the local 
control in the two groups. In the light of the above con-
siderations, marginal recurrences appear to be the most 
adequate indications for re-treatments with plaques [30]. 
Supported by our experience, we suggest that clinical 
implementation of validated nomograms [31] based on 
large patient cohorts may contribute to a better patient 
selection [32]. There are existing experiences in the litera-
ture regarding similar approaches for data collection and 
sharing [33], especially in the head and neck region [34]. 
In the presented study, local tumor control after 
a mean follow-up of 44.2 months was 100% and no pa-
tients underwent a secondary enucleation due to re-treat-
ment failure. Distant metastasis occurred in 1 patient 
after six months. As reported by Marucci et al. [27], the 
survival in the re-irradiated patients was not compro-
mised by a second course of irradiation. In our study, all 
patients were initially treated with Ruthenium plaques, 
and were re-irradiated with Ruthenium-106 plaque in 
three cases and with Iodine-125 in two cases. In second 
procedure, the mean total dose delivered to the sclera 
was 495 Gy. The therapeutic approach was personalized 
in order to obtain the best functional and local control 
outcomes [35]. No patients developed scleral necrosis 
during follow-up. Scleral necrosis is an uncommon com-
plication of radiation therapy because of the radioresis-
tant nature of this avascular, hypocellular, and relatively 
inactive tissue [36]. It has been reported as a side effect of 
brachytherapy, with an incidence of up to 14% [37]. After 
Iodine-125 plaque radiotherapy of melanomas, Shields 
et al. [2] found 1% of cases with scleral melting, all in-
cluded cases of ciliochoroidal melanomas, two of which 
had a temporarily rectus muscle disinsertion. Although 
second course of brachytherapy allows the preservation 
of an eyeball, the procedure may increase ocular morbid-
ity and the risk of vision-threating ocular side effects. In 
our patient cohort, cataract occurred in two patients af-
ter re-treatment. After a median follow-up of 44.2 (range, 
26-65) from re-treatment, all patients evolved with wors-
ening of the visual acuity: median visual acuity was 0.42 
at the time of recurrence and declined to 0.24 at the most 
recent follow-up. 
Conclusions 
In summary, our experience and the systematic re-
view suggest that, in selected cases (especially in the 
presence of marginal local recurrences), a personalized 
re-treatment approach with plaques may offer high prob-
ability of tumor control and eye preservation, but a wors-
ening of the visual function may occur. 
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